公开(公告)号：US20240360162A1

公开(公告)日：2024-10-31

申请号：US18767494

申请日：2024-07-09

申请人： Compass Pathfinder Limited

发明人： Derek John LONDESBROUGH ,  Christopher BROWN ,  Julian Scott NORTHEN ,  Gillian MOORE ,  Hemant Kashinath PATIL ,  David E. NICHOLS

IPC分类号： C07F9/572 ,  A61K9/00 ,  A61K9/20 ,  A61K47/36 ,  A61K47/38 ,  C07D209/16

CPC分类号： C07F9/5728 ,  A61K9/0053 ,  A61K9/2054 ,  A61K47/36 ,  A61K47/38 ,  C07D209/16 ,  C07B2200/13

摘要： This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

公开(公告)号：US20240358686A1

公开(公告)日：2024-10-31

申请号：US18770456

申请日：2024-07-11

申请人： FIDELITY BIOPHARMA CO.

发明人： Gang CHEN ,  Gongzheng CHEN ,  Song LIN ,  Rashmi Rohit PRASADE ,  Ganesh Dattatray CHAVAN PATIL

IPC分类号： A61K31/433 ,  A61K9/00 ,  A61K9/08 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/18 ,  A61K47/26 ,  A61K47/38

CPC分类号： A61K31/433 ,  A61K9/0053 ,  A61K9/08 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/183 ,  A61K47/26 ,  A61K47/38

摘要： A tizanidine liquid preparation and use of the tizanidine liquid preparation in the preparation of a medicament for treating muscle spasm, wherein the tizanidine liquid preparation comprises an active ingredient, disodium EDTA and other pharmaceutical excipients, wherein the active ingredient is one or more of tizanidine or a pharmaceutically acceptable salt, solvate and hydrate thereof.

公开(公告)号：US20240358681A1

公开(公告)日：2024-10-31

申请号：US18566516

申请日：2022-06-02

申请人： Mitobridge, Inc. ,  Astellas Pharma, Inc.

发明人： Naotoshi Kanemitsu ,  Mototsugu Ito ,  George Mulligan ,  Seiji Takae ,  Marina Tanaka

IPC分类号： A61K31/4174 ,  A61K47/12 ,  A61K47/26 ,  A61K47/38 ,  A61P3/00

CPC分类号： A61K31/4174 ,  A61K47/12 ,  A61K47/26 ,  A61K47/38 ,  A61P3/00

摘要： The present disclosure relates to methods of use of an agonist of peroxisome proliferator-activated receptors delta (PPARδ) (e.g., Compound (I) or a pharmaceutically acceptable salt thereof disclosed herein), for example, for treating patients having primary mitochondrial myopathies (PMM). The present disclosure also relates to a pharmaceutical composition comprising an agonist of peroxisome proliferator-activated receptors delta (PPARδ) and croscarmellose sodium.

公开(公告)号：US20240358646A1

公开(公告)日：2024-10-31

申请号：US18563517

申请日：2022-05-19

申请人： Evonik Operations GmbH

发明人： Hans Bär ,  Felix Hofmann ,  Steven Smith ,  Peter Niepoth ,  Rima Jaber ,  Bettina Hölzer

IPC分类号： A61K9/48 ,  A61K47/14 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38

CPC分类号： A61K9/4808 ,  A61K9/4891 ,  A61K47/14 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38

摘要： A process for preparing a polymer-coated hard shell capsule can be performed. The hard shell capsule has a body and a cap. In the closed state the cap overlaps the body either in a pre-locked state or in a final-locked state. The hard shell capsule is provided in the pre-locked state and coated with a coating solution, suspension or dispersion that has at least one polymer; at least one glidant; at least one emulsifier; optionally at least one plasticizer; optionally at least one biologically active ingredient; and optionally at least one additive, different from the above. The process is used to obtain a coated, preferably only at the outer surface, hard shell capsule in the pre-locked state, wherein the coating solution, suspension or dispersion has a surface tension of at most 38 mN/m. The polymer-coated hard shell capsule obtained from the process is used for immediate, delayed or sustained release.

公开(公告)号：US12121537B2

公开(公告)日：2024-10-22

申请号：US17936361

申请日：2022-09-28

申请人： RHA INVESTMENT LIMITED

发明人： Shawn J. Green

IPC分类号： A61K36/00 ,  A23L33/00 ,  A23L33/105 ,  A23L33/15 ,  A23L33/16 ,  A61K9/00 ,  A61K9/20 ,  A61K31/375 ,  A61K31/51 ,  A61K31/519 ,  A61K31/714 ,  A61K33/00 ,  A61K33/06 ,  A61K36/185 ,  A61K36/21 ,  A61K36/74 ,  A61K47/02 ,  A61K47/12 ,  A61K47/38 ,  A61K47/46

CPC分类号： A61K33/00 ,  A23L33/105 ,  A23L33/15 ,  A23L33/16 ,  A23L33/30 ,  A61K9/0056 ,  A61K9/0095 ,  A61K9/2054 ,  A61K9/2068 ,  A61K31/375 ,  A61K31/51 ,  A61K31/519 ,  A61K31/714 ,  A61K33/06 ,  A61K36/185 ,  A61K36/21 ,  A61K36/74 ,  A61K47/02 ,  A61K47/12 ,  A61K47/38 ,  A61K47/46 ,  A23V2002/00 ,  A61K36/74 ,  A61K2300/00 ,  A61K36/185 ,  A61K2300/00

摘要： Compositions and methods for improving nitric oxide levels in a subject, comprising administering to a subject, a composition comprising dietary nitrate derived from potassium nitrate, beet root (whole plant, powder, plant extract), and/or nitrate-rich leafy green portions (whole plant, powder, plant extract) that improve functional nitric oxide levels in subjects as shown by increasing salivary bioconversion of nitrate to nitrite, a necessary a required step for nitric oxide mediated health benefits. The disclosed novel compositions improve cardiac health, lowers blood pressure, intraocular pressure, and LDL and restores nitric oxide mediated cardiovascular benefits, including but not limited, restoring endothelium function and improving flow mediated dilation.

公开(公告)号：US20240342183A1

公开(公告)日：2024-10-17

申请号：US18752293

申请日：2024-06-24

申请人： OWP Pharmaceuticals, Inc.

发明人： Paul Sudhakar ,  Scott Boyer

IPC分类号： A61K31/53 ,  A61K9/00 ,  A61K47/02 ,  A61K47/06 ,  A61K47/10 ,  A61K47/26 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38

CPC分类号： A61K31/53 ,  A61K9/0053 ,  A61K47/02 ,  A61K47/06 ,  A61K47/10 ,  A61K47/26 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38

摘要： The present invention relates to an oral liquid suspension that includes lamotrigine and methods of medical treatment that include administering the oral liquid suspension. The oral liquid suspension has desirable physicochemical properties and technical attributes. The oral liquid suspension is useful in patients having difficulties in swallowing tablets and provide medical practitioners with additional options for dose titration.

公开(公告)号：US20240335389A1

公开(公告)日：2024-10-10

申请号：US18131908

申请日：2023-04-07

申请人： HUAQIAO UNIVERSITY

发明人： Meitian XIAO ,  Chuqi He ,  Chaoxing Chen ,  Jing Ye ,  Shipeng Chen ,  Yucheng Yang ,  Yayan Huang ,  Bingde Zheng ,  Xueqin Zhang ,  Na Zhang

IPC分类号： A61K9/48 ,  A61K47/38

CPC分类号： A61K9/4816 ,  A61K47/38

摘要： A method for preparing a plant-based hard capsule for rapid disintegration, the method comprises: weighing a coagulant aid, dissolving in distilled water at 75-90° C., and stirring to obtain a first solution; maintaining a temperature of the first solution at 75-90° C., adding a gel-forming agent, and stirring; adding a film-forming agent with a weight percentage of 5%-25%, stirring, finally adding a plasticizer by a weight percentage of 0-3%, and stirring until the film-forming agent and the plasticizer are completely dissolved to obtain a material solution; leaving the material solution to stand at 45-60° C. to obtain a gel solution; and cooling the gel solution to 40-50° C., dipping the gel solution for forming, and drying for 100-200 minutes under a condition of 20-35° C. and a 40%-60% relative humidity; and demoulding, cutting, and combining together by sleeving to obtain the plant-based hard capsule for the rapid disintegration.

公开(公告)号：US20240325367A1

公开(公告)日：2024-10-03

申请号：US18554118

申请日：2022-03-09

申请人： ZHEJIANG CUIZE PHARMACEUTICAL TECHNOLOGY CO., LTD.

发明人： Siping SUN ,  Liang ZENG ,  Qiang GE ,  Dingqiang JIANG

IPC分类号： A61K31/445 ,  A61K9/00 ,  A61K9/14 ,  A61K47/02 ,  A61K47/10 ,  A61K47/38

CPC分类号： A61K31/445 ,  A61K9/0019 ,  A61K9/14 ,  A61K47/02 ,  A61K47/10 ,  A61K47/38

摘要： The present disclosure relates to a ropivacaine suspension injection, and a preparation method therefor. Specifically, the ropivacaine suspension injection of the present disclosure comprises ropivacaine and a pharmaceutically acceptable excipient, wherein the median particle size D50 of the suspension injection is within the range of 1 μm to 40 μm. The ropivacaine suspension injection of the present disclosure can continuously release a drug in vivo, and has an analgesic effect of no less than 12 h, preferably, an analgesic effect of no less than 24 h, and more preferably, an analgesic effect of no less than 72 h.

公开(公告)号：US20240325305A1

公开(公告)日：2024-10-03

申请号：US18264938

申请日：2022-02-10

申请人： BIOTHERAVISION INC.

发明人： Roland Bodmeier ,  Chin-Ming Chang

IPC分类号： A61K9/10 ,  A61K9/00 ,  A61K31/407 ,  A61K31/56 ,  A61K47/10 ,  A61K47/18 ,  A61K47/32 ,  A61K47/38 ,  A61K47/40

CPC分类号： A61K9/10 ,  A61K9/0048 ,  A61K31/407 ,  A61K31/56 ,  A61K47/10 ,  A61K47/183 ,  A61K47/186 ,  A61K47/32 ,  A61K47/38 ,  A61K47/40

摘要： The invention provides an aqueous liquid composition for ophthalmic administration, comprising therapeutically effective amounts of a ketorolac compound and of a corticosteroid, wherein the ketorolac compound is present in an essentially dissolved form; wherein the corticosteroid is present in the form of suspended particles; and wherein the composition exhibits an acidic pH of about 6.5 or less. The invention further provides compositions as disclosed herein for use in the prevention or treatment of ocular inflammation and methods for preventing or treating ocular inflammation in a subject.

公开(公告)号：US20240325300A1

公开(公告)日：2024-10-03

申请号：US18511751

申请日：2023-11-16

申请人： KING FAISAL UNIVERSITY

发明人： HANY MOHAMED ABD EL-LATEEF AHMED ,  MAI MOSTAFA KHALAF ALI ,  MOHAMED AHMED EL-MOKHTAR ,  MOHAMMED SHERIF SADDIK ,  AHMED MOHAMMED ABU-DIEF MOHAMMED

IPC分类号： A61K9/06 ,  A61K31/5377 ,  A61K31/546 ,  A61K47/38 ,  A61K47/69 ,  A61P17/02 ,  A61P31/04

CPC分类号： A61K9/06 ,  A61K31/5377 ,  A61K31/546 ,  A61K47/38 ,  A61K47/6903 ,  A61P17/02 ,  A61P31/04 ,  B82Y5/00

摘要： A combination treatment for antibiotic resistant infections is provided. The combination treatment for antibiotic resistant infections includes zinc oxide nanoparticles loaded with linezolid and ceftriaxone. The combination treatment may be formulated for administration by any desired route, including particularly oral administration or topical administration. The combination treatment may be administered to a subject in need thereof to treat a bacterial infection. The bacterial infection may be caused by any bacterium, including an antibiotic resistant bacterium. The combination treatment may be formulated in a gel for topical administration to improve wound healing and to treat a MRSA infection.